Bob Kyne is a Scientist II in the Chemical Biology group at Celgene Corp., located in Cambridge, MA. During his time at Celgene, Bob has contributed to the development of several target ID platforms and the expansion into new druggable modalities. Previously, Bob was a Senior Scientist in the BioTherapeutics medicinal chemistry group of Pfizer, Inc., located in Groton, CT. There, in addition to working on several ongoing drug discovery programs, Bob contributed to the discovery of sulfonyl fluorides as selective tyrosine warheads, the use of clickable photoaffinity labels for target ID/validation, and the utilization of CETSA as an orthogonal method for target confirmation. Concurrently, he served as an adjunct Assistant Professor at Connecticut College, teaching organic chemistry laboratory courses and mentoring students. Bob received his Ph.D. from Boston College under the direction of Professor James P. Morken, where he developed a variety of metal-catalyzed & metal-free methodologies involving allyl-boron nucleophiles. He graduated with honors from Connecticut College in 2007 with a B.A. in the ACS Certified Major in Chemistry. During his time there he worked in the laboratories of Professor Timo V. Ovaska, where he published on several methodologies and the first total synthesis of (±)-frondosin C.